All In Biotech

NDA 207924 · Eli Lilly and CO

Olumiant

Baricitinib · Oral · Janus Kinase Inhibitor

NovelBreakthrough therapy

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

May 31, 2018

Approved uses

6

Original approval plus efficacy supplements

Registered trials

173

61 Phase 3, 38 recruiting

FAERS reports

9,777

6,825 serious, 891 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS See full prescribing information for complete boxed warning. Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment with OLUMIANT if serious infection occurs until the infection is controlled. OLUMIANT should not be given to patients with active TB. Test for latent TB before and during therapy, except for COVID-19; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. ( 5.1 ) Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase (JAK)...

What it is approved for

From the label in effect Oct 9, 2026.

OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for the treatment of: Moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) Severe alopecia areata (AA) in adults and pediatric patients 12 years of age and older. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 ) 1.1 Moderately to Severely Active Rheumatoid Arthritis OLUMIANT ® is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine. 1.2 Coronavirus Disease 2019 (COVID-19) OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.3 Severe Alopecia Areata OLUMIANT is indicated for the treatment of severe alopecia areata in adults and pediatric patients 12 years of age and older. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators,...

Mechanism: Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Baricitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • OLUMIANT · BARICITINIB 1MG · TABLET, ORAL · Prescription · TE AB
  • OLUMIANT · BARICITINIB 4MG · TABLET, ORAL · Prescription · TE AB
  • OLUMIANT · BARICITINIB 2MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Baricitinib" as an intervention, any sponsor and status, largest first.

All 173 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective786
  • off label use759
  • covid-19458
  • rheumatoid arthritis413
  • pulmonary embolism309
  • pneumonia285
  • headache269
  • herpes zoster243
  • death237
  • nausea237
  • deep vein thrombosis215
  • arthralgia191

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
20131
20141
20152
20161
20178
2018314
20191,085
2020846
20211,574
20221,436
20231,654
20241,408
2025944
2026502

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Olumiant (Baricitinib)

2024 spending

$35.4M

Beneficiaries

1,609

9,553 claims

Per beneficiary

$22,011

$104.76 per unit

View as table
YearSpending
2020$18,695,163
2021$19,305,940
2022$21,134,588
2023$28,345,232
2024$35,415,629

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 316 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.